Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acclarent Expects TruDi Shaver Blade To Prevent Repeat ENT Surgeries

Executive Summary

The FDA recently cleared the TruDi Shaver Blade, an electromagnetically navigated blade for the incision and removal of soft and hard tissue or bone in ear, nose, throat, and maxillofacial surgery, as well as head and neck and skull-base surgery.

You may also be interested in...



Medtronic Bolsters Sinus Portfolio With $1.1Bn Intersect ENT Buyout

Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.

Ortho Demand Pull: DePuy Synthes Shaping Its Digital And Robotic Surgery Strategy Around Patient Needs

Johnson & Johnson's DePuy Synthes orthopedic business has taken a measured view of digital and robotic capabilities, rather than acquiring assets that perhaps do not fully meet its strategic needs. For the business's global R&D head Euan Thomson, any new technology must augment the group's abilities to drive meaningful outcomes.

Device Debut: STS' Stent For Chronic Sinusitis Gets US Go-Ahead

The Israeli portfolio company of The Trendlines Group announced that US FDA 510(k)-cleared its composite removable sinus stent system based on results of a 30-patient trial.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel